Fig. 1: NSs reduces cell viability and induces cytotoxicity in cancer cell lines.
From: Harnessing Rift Valley fever virus NSs gene for cancer gene therapy
A Bright field images of cells transfected with 2.5 ng of NSs mRNA, NSs mutant mRNA, GFP mRNA, or mock treatment and captured at 48 h post-transfection. H1299, Hep3B, and HeLa cells were transfected at 2.5 ng mRNA. Scale bar = 100 µm (B) AlamarBlue cell viability assays were conducted on H1299 and Hep3B cells transfected with dose titrations ranging from 0.6 to 5 ng of NSs, NSs mutant, or GFP control mRNA at 48 h post-transfection. The treatments were made relative to the mock control set at 100% (C) Time course proliferation analysis of H1299 cells transfected with NSs, NSs mutant, or GFP mRNA over 72 h. D Cytotox96 assay was performed to measure Lactate Dehydrogenase (LDH) release in H1299 cells transfected with NSs, NSs mutant, or luciferase control mRNA at 48 h post-transfection. A positive control that induced cell lysis was included to demonstrate maximal LDH release. The treatments were made relative to the luciferase mRNA control set at 1. Data presented as the mean ± S.D of triplicate treated cells. These data are one representative experiment that was performed two times.
